Elena Stylianou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3058449/publications.pdf Version: 2024-02-01



FLENA STYLIANOU

#	Article	IF	CITATIONS
1	Identification of antigens presented by MHC for vaccines against tuberculosis. Npj Vaccines, 2020, 5, 2.	6.0	69
2	Nitric Oxide Modulates Metabolic Remodeling in Inflammatory Macrophages through TCA Cycle Regulation and Itaconate Accumulation. Cell Reports, 2019, 28, 218-230.e7.	6.4	149
3	Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. Expert Review of Vaccines, 2019, 18, 1271-1284.	4.4	37
4	Cytomegalovirus infection is a risk factor for tuberculosis disease in infants. JCI Insight, 2019, 4, .	5.0	42
5	Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine. Infection and Immunity, 2018, 86, .	2.2	70
6	Regulation of mycobacterial infection by macrophage Gch1 and tetrahydrobiopterin. Nature Communications, 2018, 9, 5409.	12.8	24
7	Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection. Scientific Reports, 2018, 8, 14480.	3.3	43
8	The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010–2014. Vaccine Journal, 2017, 24, .	3.1	41
9	T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nature Communications, 2016, 7, 11290.	12.8	236
10	A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis. BMC Infectious Diseases, 2016, 16, 412.	2.9	27
11	Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis. Tuberculosis, 2014, 94, 226-237.	1.9	71
12	Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M.Âtb). Tuberculosis, 2013, 93, 551-557.	1.9	45